The Europe coagulation market was valued at US$2.00 billion in 2022 and is expected to reach US$3.37 billion by 2030; it is estimated to grow at a CAGR of 6.8% from 2022 to 2030.
A coagulation test helps prevent potential heart attack-causing blood clotting. A coagulation analyzer is used during coronary artery bypass surgery and angioplasty to monitor information on blood clotting status. Thus, the growing incidence of cardiovascular diseases bolsters the coagulation market growth.
A large number of people in Germany are suffering from cardiovascular disorders, which can be attributed to the growing aging population in the country. Heart attack is the most serious consequence of coronary heart disease (CHD). More than 3.6 million of the German population have been diagnosed with CHD till date, and over 1.3 million have survived a stroke. According to the latest WHO data published in 2020, the count of deaths caused by CHD in Germany reached 147,055 (i.e., 20.98% of total deaths).
Based on disease indication, the Europe coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand's disease, and others. The liver disease segment held the largest Europe coagulation market share in 2022.
Based on type, the Europe coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held a larger Europe coagulation market share in 2022. Clinical laboratory analysers segment is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.
In terms of offering, the Europe coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held a larger Europe coagulation market share in 2022. Diagnosis segment is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment segment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.
By technology, the Europe coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held the largest Europe coagulation market share in 2022.
By end user, the Europe coagulation market is segmented into clinical laboratories, hospitals, and others. The hospitals segment held the largest Europe coagulation market share in 2022.
Based on country, the Europe coagulation market is categorized into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Germany dominated the Europe coagulation market in 2022.
F. Hoffmann-La Roche Ltd; Genrui Biotech Co., Ltd.; Horiba Ltd; ImproGen Diagnostik Kimya San. & Tic. Ltd.Şti.; Siemens Healthineers AG; Sysmex Corp; Transasia Bio-Medicals Ltd; and Nordic Biomarker AB are some of the leading companies operating in the Europe coagulation market.
Rising Prevalence of Cardiovascular Diseases Fuel Europe Coagulation Market
Heart disease is one of the leading causes of hospitalization, death, and reduced physical performance due to conditions such as atrial fibrillation and stroke. It affects the hemostatic system, vascular system, and fluid dynamics of blood and causes arterial and venous thrombosis. Thrombosis is the leading cause of death and complications from cardiovascular disease. Blood vessels damaged by smoking and high blood pressure form cholesterol-rich plaques lining the blood vessels, which can rupture and cause platelets to clot. With coagulation disorders, there is a risk of myocardial infarction, stroke, and atherothrombotic events in the vascular beds. Heart failure (HF) is related to an increased risk of thromboembolism independent of the presence of atrial fibrillation (AF). Platelet activation and coagulation system abnormalities can increase the risk of serious thromboembolic events in patients suffering from HF.A coagulation test helps prevent potential heart attack-causing blood clotting. A coagulation analyzer is used during coronary artery bypass surgery and angioplasty to monitor information on blood clotting status. Thus, the growing incidence of cardiovascular diseases bolsters the coagulation market growth.
Europe Coagulation Market Overview
The Europe coagulation market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Europe holds a significant position in the global coagulation market and is estimated to register a robust CAGR during 2022-2030. Market growth in this region is mainly attributed to the rising incidence of cardiovascular disorders, increasing advancements in medical devices, the growing aging population, and the surging awareness of coagulation analyzers.A large number of people in Germany are suffering from cardiovascular disorders, which can be attributed to the growing aging population in the country. Heart attack is the most serious consequence of coronary heart disease (CHD). More than 3.6 million of the German population have been diagnosed with CHD till date, and over 1.3 million have survived a stroke. According to the latest WHO data published in 2020, the count of deaths caused by CHD in Germany reached 147,055 (i.e., 20.98% of total deaths).
Europe Coagulation Market Segmentation
The Europe coagulation market is segmented based on disease indication, type, offering, technology, end user, and country.Based on disease indication, the Europe coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand's disease, and others. The liver disease segment held the largest Europe coagulation market share in 2022.
Based on type, the Europe coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held a larger Europe coagulation market share in 2022. Clinical laboratory analysers segment is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.
In terms of offering, the Europe coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held a larger Europe coagulation market share in 2022. Diagnosis segment is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment segment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.
By technology, the Europe coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held the largest Europe coagulation market share in 2022.
By end user, the Europe coagulation market is segmented into clinical laboratories, hospitals, and others. The hospitals segment held the largest Europe coagulation market share in 2022.
Based on country, the Europe coagulation market is categorized into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Germany dominated the Europe coagulation market in 2022.
F. Hoffmann-La Roche Ltd; Genrui Biotech Co., Ltd.; Horiba Ltd; ImproGen Diagnostik Kimya San. & Tic. Ltd.Şti.; Siemens Healthineers AG; Sysmex Corp; Transasia Bio-Medicals Ltd; and Nordic Biomarker AB are some of the leading companies operating in the Europe coagulation market.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Europe Coagulation Market - Key Industry Dynamics
5. Coagulation Market - Europe Market Analysis
6. Europe Coagulation Market - Revenue and Forecast to 2030 - by Disease Indication
7. Europe Coagulation Market - Revenue and Forecast to 2030 - by Type
8. Europe Coagulation Market - Revenue and Forecast to 2030 - by Offering
9. Europe Coagulation Market - Revenue and Forecast to 2030 - by Technology
10. Europe Coagulation Market - Revenue and Forecast to 2030 - by End User
11. Europe Coagulation Market - Country Analysis
12. Europe Coagulation Market-Industry Landscape
13. Company Profiles
14. Appendix
List of Tables
List of Figures
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- Genrui Biotech Co., Ltd
- Horiba Ltd.
- ImproGen Diagnostik Kimya San. & Tic. Ltd.Şti.
- Nordic Biomarker AB
- Siemens Healthineers AG
- Sysmex Corp
- Transasia Bio-Medicals Ltd
